Brief Report: Urine Tenofovir Levels Strongly Correlate with Virologic Suppression in Patients with HIV on Tenofovir Alafenamide-Based Antiretroviral Therapy.

Kelly A JohnsonHideaki OkochiMireya ArreguinJoseph WatabeDavid V GliddenAnindita ChattopadhyayElizabeth ImbertMatthew D HickeyMonica GandhiMatthew Spinelli

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

We found that urine tenofovir (TFV) levels >1500 ng/ml strongly predict virologic suppression among patients with HIV taking tenofovir alafenamide (TAF, OR 5.66; 95% CI 1.59-20.14; p = 0.007). This suggests an existing point-of-care assay developed for tenofovir disoproxil fumarate (TDF) will support adherence monitoring for patients on all TFV-based antiretrovirals.

Keyphrases

antiretroviral therapy
hiv infected
hiv positive
human immunodeficiency virus
hiv infected patients
hiv aids
newly diagnosed
ejection fraction
type diabetes
prognostic factors
high throughput
hepatitis c virus
metabolic syndrome
south africa
glycemic control
men who have sex with men
weight loss